Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression

Kinome-wide shRNA Screen Identifies the Receptor Tyrosine Kinase AXL as a Key Regulator for Mesenchymal Glioblastoma Stem-like Cells

(2015) Peng Cheng et al.   Stem Cell Reports

Chemoradiation provides a physiological selective pressure that increases the expansion of aberrant TP53 tumor variants in residual rectal cancerous regions

(2015) Kazuko Sakai et al.   Oncotarget

Large-Scale East-Asian eQTL Mapping Reveals Novel Candidate Genes for LD Mapping and the Genomic Landscape of Transcriptional Effects of Sequence Variants

(2014) Maiko Narahara et al.   PLoS One

Prognostic and Clinicopathological Significance of Downregulated E-Cadherin Expression in Patients with Non-Small Cell Lung Cancer (NSCLC): A Meta-Analysis

(2014) Yan-Long Yang et al.   PLoS One

MET and AXL Inhibitor NPS-1034 Exerts Efficacy against Lung Cancer Cells Resistant to EGFR Kinase Inhibitors Because of MET or AXL Activation

(2013) J. K. Rho et al.   CANCER RESEARCH

AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells

(2013) M K Asiedu et al.   ONCOGENE

The receptor tyrosine kinase Axl regulates cell–cell adhesion and stemness in cutaneous squamous cell carcinoma

(2013) M A Cichoń et al.   ONCOGENE

Higher Expression of Receptor Tyrosine Kinase Axl, and Differential Expression of its Ligand, Gas6, Predict Poor Survival in Lung Adenocarcinoma Patients

(2012) Masashi Ishikawa et al.   ANNALS OF SURGICAL ONCOLOGY

ABL Regulation by AXL Promotes Cisplatin Resistance in Esophageal Cancer

(2012) J. Hong et al.   CANCER RESEARCH

AXL and acquired resistance to EGFR inhibitors

(2012) Sophie Postel-Vinay et al.   NATURE GENETICS

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

(2012) Zhenfeng Zhang et al.   NATURE GENETICS

KIF5B-RET fusions in lung adenocarcinoma

(2012) Takashi Kohno et al.   NATURE MEDICINE

HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation

(2012) Ken Takezawa et al.   Cancer Discovery

Lung cancers unrelated to smoking: characterized by single oncogene addiction?

(2011) Kenichi Suda et al.   International Journal of Clinical Oncology

International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

(2011) William D. Travis et al.   Journal of Thoracic Oncology

Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases

(2011) Akihiko Yoshizawa et al.   MODERN PATHOLOGY

A Grading System of Lung Adenocarcinomas Based on Histologic Pattern is Predictive of Disease Recurrence in Stage I Tumors

(2010) Gabriel Sica et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma

(2010) Xianzhou Song et al.   CANCER

Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation

(2010) Kenichi Suda et al.   CANCER AND METASTASIS REVIEWS

AXL Is an Essential Factor and Therapeutic Target for Metastatic Ovarian Cancer

(2010) E. B. Rankin et al.   CANCER RESEARCH

Differential Expression of Axl and Gas6 in Renal Cell Carcinoma Reflecting Tumor Advancement and Survival

(2009) A. Gustafsson et al.   CLINICAL CANCER RESEARCH

Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival

(2009) C. Gjerdrum et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA